KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Invested Capital (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Invested Capital for 8 consecutive years, with $437.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 6.63% year-over-year to $437.8 million, compared with a TTM value of $437.8 million through Sep 2025, down 6.63%, and an annual FY2024 reading of $450.1 million, down 3.84% over the prior year.
  • Invested Capital was $437.8 million for Q3 2025 at Aurinia Pharmaceuticals, up from $410.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $485.7 million in Q2 2023 and bottomed at $298.2 million in Q3 2021.
  • Average Invested Capital over 5 years is $425.0 million, with a median of $437.8 million recorded in 2025.
  • The sharpest move saw Invested Capital dropped 27.17% in 2021, then surged 42.01% in 2022.
  • Year by year, Invested Capital stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then rose by 15.44% to $468.1 million in 2023, then dropped by 3.84% to $450.1 million in 2024, then decreased by 2.73% to $437.8 million in 2025.
  • Business Quant data shows Invested Capital for AUPH at $437.8 million in Q3 2025, $410.8 million in Q2 2025, and $421.5 million in Q1 2025.